by Maria Zannes | Aug 1, 2018 | Press Releases
JULY 31, 2018 (San Antonio, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin Y. Meghji, managing partner of M-III Partners L.P. (M-III), to its Board of...
by Maria Zannes | Jul 24, 2018 | News
JULY 20, 2018 As published in GenomeWeb’s 360Dx By Leo O’Connor NEW YORK – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples. The San...
by Maria Zannes | Jul 24, 2018 | News
JULY 19, 2018 As published in the San Antonio Business Journal By W. Scott Bailey Roughly four years after its San Antonio launch, cancer diagnostics company bioAffinity Technologies is only months away from taking its initial product — CyPath Lung — to market. The...
by Maria Zannes | Jul 23, 2018 | Press Releases
JULY 17, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. Recruitment is...
by Maria Zannes | May 18, 2018 | News
MAY 15, 2018 As published in Xconomy Texas By David Holley (SAN ANTONIO, TX) bioAffinity, the maker of a cancer diagnostic test, has added Peter Knight, who was the chief of staff for Al Gore when he was in Congress, to its board of directors and is in the process of...